Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-944 Phase 2 Part A in adults with essential tremor
ACTRN12619001052123Phase 2Recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ulixacaltamide in essential tremor (ET), sponsored by Praxis Precision Medicines. Primary endpoint: Efficacy of PRAX-944 on upper limb tremor assessed by the Essential Tremor Rating Assessment Scale (TETRAS) at Day 14. Started Mar 2020; status: recruiting.
02
Drugs
ulixacaltamide
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on ACTRN12619001052123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001052123.